
|Videos|July 31, 2020
AsclepiX lead candidate holds potential for wet AMD, DME, RVO (ASRS 2020)
Author(s)Alex Delaney-Gesing , Sheryl Stevenson
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
3
Neurotrophic keratitis outcomes improve with early, stage-based care
4
Alcon raises offer in amended deal to acquire STAAR Surgical
5













































.png)


